Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould raised the price target on Abbvie (NYSE: ABBV) to $265.00 (from $240.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
